complying with regulatory requirements or operating the facility and risk related to the COVID-19 pandemic. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended...
“Seagen delivered strong performance in the first quarter, with significant growth of 22 percent for both total revenue and net product sales, compared to 2022, driven by our multi-product commercial portfolio,” said David Epstein, Chief Executive Officer of Seagen. “This month the FDA granted...
Seagen and Sanofi will also unveil the first preclinical data from a novel topoisomerase I inhibitor ADC targeting CEACAM5, showing potent antitumor activity in patient-derived colorectal cancer models. These are the first data disclosed from the...
公告Annual report [Section 13 and 15(d), not S-K Item 405] Seagen Inc资讯 02-20 06:27 490 0 公告Statement of changes in beneficial ownership of securities Seagen Inc资讯 02-18 09:00 498 0 公告Statement of changes in beneficial ownership of securities ...
“Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a resu...
“Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking...
engagement with China is complex. The two sides have agreed that pending the final settlement of the boundary question, maintenance of peace and tranquility in the border areas is an essential basis for the overall development of the bilateral relationship," the MEA's annual report for 2022 said...
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen January 15, 2025 · 4 min read · Tristan Manalac Sickle cell disease Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024 December 9, 2024 · 2 min read...
More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commi...